Skip to main content
Download PDF

Communication between mitochondria and other organelles: a brand-new perspective on mitochondria in cancer

Cell & Bioscience volume 9, Article number: 27 (2019) Cite this article

Abstract

Mitochondria are energy factories of cells and are important pivots for intracellular interactions with other organelles. They interact with the endoplasmic reticulum, peroxisomes, and nucleus through signal transduction, vesicle transport, and membrane contact sites to regulate energy metabolism, biosynthesis, immune response, and cell turnover. However, when the communication between organelles fails and the mitochondria are dysfunctional, it may induce tumorigenesis. In this review, we elaborate on how mitochondria interact with the endoplasmic reticulum, peroxisomes, and cell nuclei, as well as the relation between organelle communication and tumor development

.

Introduction

The mitochondrion is a double membrane-bound half-independent organelle that shoulders most of the metabolic activities in the cell. The mitochondria modulate cell metabolism, reactive oxygen species (ROS) genesis, cell apoptosis, and the universal second messenger, calcium [1].

Mitochondria, as energy centers, play an important role in cancer metabolism. The first description of the function of mitochondria in tumorigenesis used the term ‘aerobic glycolysis’, which is now known as the Warburg effect [2]. This effect is based on the fact that tumor cells use glycolysis rather than the tricarboxylic acid (TCA) cycle for energy production. Warburg attributed this phenomenon to mitochondrial dysfunction in tumor cells and suggested that destruction of the mitochondrial respiratory chain caused tumor cells to rely on glycolysis. However, mitochondrial dysfunction is not considered a hallmark of cancer, as it also correlated with other diseases such as heart failure, diabetes, hepatocerebral disorder, juvenile catastrophic epilepsy, and neurodegenerative diseases [3,4,5]. Additionally, tumor cells require fully functional mitochondria. The conditions of tumor cells are quite different from those of normal cells; in fact, tumor cells develop new mechanisms to adapt to these changes.

Meanwhile, as an important organelle, the stability of the mitochondria requires not only its own regulation but also a finely tuned interplay with other organelles [4]. These organelles constitute a complicated network, and the dysregulation of one of the downstream pathways may lead to severe mitochondrial dysfunction, resulting in their failure to regulate energy metabolism and ion buffering.

The crosstalk between mitochondria and other organelles is important in tumorigenesis; because the organelles work as an entity, any impairment in the relevant cascades may lead to change in cell microenvironment, activation of certain oncogenes, and mitochondrial genome mutation. This review introduces the connections between the mitochondria and endoplasmic reticulum (ER), mitochondria and peroxisome, and mitochondria and nucleus in physiological and pathological conditions, as well as the impact of this crosstalk in cancer pathogenesis.

Mitochondria and ER

In the past few decades, several studies have shown that mitochondria are widely associated with the ER. There are many ways in which the ER can interact with the mitochondria. However, the most important way is through their membrane structures, which contact each other but do not fuse; so, they retain their individual characteristics. The area of close contact between the mitochondria and the ER membrane can be observed in animal cells by electron microscopy and fluorescence microscopy. The contact point is 10–30 nm wide, where it can attach to ribosomes [6]. The contact points between the mitochondria and the ER are relatively stable. When the ER and mitochondria move along the cytoskeleton, the two organelles maintain contact with each other.

Relatively stable contacts provide the basis for the interaction between ER and mitochondria to coordinate cellular biological functions, such as calcium ion (calcium) signaling, apoptosis regulation, ER stress response, phospholipid synthesis, and translocation of the phospholipid from the ER membrane to the mitochondrial membrane. These contact sites are called mitochondria-associated ER membranes (MAMs) (Fig. 1). MAMs are rich in calcium transport channels, enzymes for lipid synthesis and transport and proteins encoded by oncogenes that regulate cellular signaling pathways, and tumor suppressors. Therefore, changes in the above mechanisms may be related to the occurrence and development of cancer. The protein on MAM may be involved in tumorigenesis and tumor progression (Table 1).

Fig. 1
figure1

The interaction between mitochondria and ER. Calcium is released via inositol 1,4,5 trisphosphate receptor (IP3R) of the endoplasmic reticulum (ER) and provides a relatively high calcium environment for mitochondria. Calcium enters the mitochondrial matrix through the voltage-dependent anion channels (VDACs) on the outer mitochondrial membrane (OMM) and through the low-affinity receptor, mitochondrial calcium uniporter (MCU) on the inner mitochondrial membrane (IMM). The glucose-regulated protein 75 (GRP-75) can be used as a partner to connect IP3R to VDACs. In addition, IP3R is regulated by numerous regulatory mechanisms. Mitofusin 2 (Mfn-2) on the ER interacts with Mfn-1 or Mfn-2 on the OMMs and regulates the connection between the two organelles. After lipid synthesis in the mitochondria or ER, a large amount of lipids is exchanged between the mitochondria and the ER in order to achieve the final lipid composition of the two organelles. This includes the processes of phosphatidylethanolamine (PE) and phosphatidylcholine (PC) synthesis and cardiolipin (CL) synthesis

Full size image
Table 1 MAMs proteins involved in tumorigenesis and tumor progression
Full size table

Calcium signal and role in the communication between mitochondria and ER

Calcium is a very important intracellular regulatory molecule. It regulates a variety of physiological and pathological processes, including cancer, and an increasing number of studies have shown that oncogenes and tumor suppressors are also related to the calcium transport system (Fig. 1).

Mitochondria and ER are important storage organelles of calcium in the cell, and calcium transfer between organelles is crucial for cell life and death [7, 8]. Calcium enters the mitochondria from the ER through MAMs and plays an important role in mitochondrial division and control of apoptosis. The uptake of calcium in the mitochondrial matrix is mainly accomplished by the low-affinity mitochondrial calcium uniporter (MCU) receptor on the inner mitochondrial membrane (IMM), and calcium passes through the outer mitochondrial membrane (OMM) relatively easily, mainly via the voltage-dependent anion channels (VDACs) [9,10,11]. Therefore, to promote the efficient uptake of calcium by mitochondria, it is necessary to generate locally high concentrations of calcium in MAMs. MAMs are highly enriched in the sensitive calcium channel’s inositol 1,4,5 trisphosphate receptor (IP3R). Under the action of IP3R and other signals, calcium in the ER is rapidly released into the surrounding cytoplasm through IP3R, exposing mitochondria to higher concentrations of calcium [12, 13].

Calcium transfer can be terminated by increasing the distance of MAMs [13, 14]. In mammalian cells, mitofusin 2 (MFN2), a family member of mitochondrial dynamics, is located in the OMM and ER surface, regulating the organelle connection between calcium-transfer sites [15,16,17]. ER-resident MFN2 interacts with mitochondrial mitofusin 1 (MFN1) and MFN2. Efficient IP3R-mediated calcium transfer to the mitochondria is achieved by the chaperone protein, a 75-kDa glucose regulatory protein (GRP75). This protein physically links the VDAC channel on the mitochondrial outer membrane to IP3R on the ER in MAMs. Knockout of GRP75 impairs IP3R-mediated transfer of calcium to the mitochondria [18].

However, this sensitive system can be utilized to achieve malignant transformation of cells. Several types of cancer cells undergo extensive reorganization of calcium signaling mechanisms to become conducive to tumorigenesis [19].

The cancer cells have altered calcium regulation mechanisms involving IP3R and VDAC, enabling the survival of cancer cells [19]. Additionally, the presence of proteins encoded by oncogenes and tumor suppressors in MAMs may alter calcium signaling in cancer cells.

Recent studies showed that disturbance in calcium homeostasis is an important mechanism of oncogene-encoded proteins and tumor suppressors to affect cancer cell fate [20]. Because IP3R is an important calcium transport system that maintains calcium homeostasis between the ER and mitochondria, some oncogene-encoded proteins and tumor suppressors have been shown to modulate IP3R activity. Therefore, IP3R is considered a molecular target for the action of oncogene-encoded proteins and tumor suppressor factors in cancer cells (Fig. 1).

IP3R is regulated by a variety of mechanisms. IP3R on the MAMs can serve as signal centers, and multiple signals can act on them. Different signals are brought together and converted to calcium signals, further affecting the function of mitochondria and even cells [21]. IP3R is over-phosphorylated in cancer cells upregulated by AKT [22]; therefore, calcium flow from the ER to mitochondria decreases, which protects cancer cells from mitochondrion-mediated apoptosis.

Thus, phosphorylated IP3R is regulated by numerous different oncogene-encoded proteins and tumor suppressors, including AKTs lipid phosphatase and negative regulators, phosphatase and tensin homolog on chromosome 10 (PTEN) [23], p53 proteins [24], and promyelocytic leukemia (PML) proteins. Studies showed that PML in MAMs is part of a complex composed of AKT. PML weakens the ability of PP2A to bind to IP3R, and PP2A does not dephosphorylate to inactivate AKT. This leads to phosphorylation of AKT, which phosphorylates IP3R and inhibits the release of calcium from protein IP3R, further protecting the mitochondria from calcium-mediated apoptosis [25]. PML is an effective tumor suppressor protein that stabilizes p53 protein and improves its function. Deletion of PML is associated with malignant pleural mesothelioma, breast cancer, etc. [26, 27]. Additionally, PML inhibits the formation of autophagosomes, thereby inhibiting autophagy induction. Decreased PML levels can also promote tumor growth by enhancing cellular autophagy [24]. Some anticancer drugs target the calcium-connected pathways [28]. For example, arsenic trioxide has a significant effect on chemotherapy for acute promyelocytic leukemia by specifically targeting PML. This chemotherapy increases the level of PML in MAMs and increases IP3R-mediated calcium transfer between the ER and mitochondria, thereby promoting the apoptosis of tumor cells and reducing autophagy [24] (Table 1).

Bcl-2 family proteins in the ER play an important role in apoptosis by controlling the integrity of mitochondrial membrane, the release of cytochrome C, and the activation of caspases [29]. It has been reported that Bcl-2 family proteins regulate the activity of IP3R [30], and different Bcl-2 proteins bind to IP3R at different sites and play different roles (Table 1). For example, Bcl-2 binds to the central region of IP3R, thereby inhibiting the function of IP3R and reducing the release of calcium, which leads to the inhibition of the apoptotic signal. Besides, BCL-XL interacts with the most C-terminal region of IP3R to promote calcium entry into the mitochondria [31]. Studies have shown that the BH4-domain of BCL-XL can selectively target and inhibit the n-terminal domain of VDAC1, while the BH4 domain of Bcl-2 is the only one involved in the inhibition of IP3Rs [32]. In addition, the interaction between Bcl-2-like protein 10 (Bcl2-L-10), a member of the anti-apoptotic Bcl-2 family of proteins, and IP3Rs-binding protein released with IP3 (IRBIT), regulates the activity of IP3R. IRBIT antagonizes Bcl2-L-10, with both proteins binding to the IP3-binding domain of IP3R1. When IRBIT and Bcl2-L-10 complexes are phosphorylated, they bind to IP3R and inhibit its activity, reducing calcium release. Under the stimulation of apoptosis, IRBIT and Bcl2-L-10 complex is dephosphorylated, separated from IP3R, and calcium is released by IP3R, resulting in calcium flowing into the mitochondria, leading to apoptosis [33].

Additionally, the sarco/endoplasmic reticulum calcium ATPase (SERCA) pump localizes to the ER membrane. It is regulated by several proteins at the ER-mitochondrial contact site to affect calcium flux. The SERCA pump ensures refilling of the ER calcium storage by actively pumping calcium ions from the cytosol to the ER, creating a high calcium gradient between these regions (~ 0.1 μM in the cytosol and ~ 400 μM in the ER) [34]. The SERCA2b subtype is the most abundant in MAMs [35]. Regulation of the activity of the SERCA pump by proteins encoded by oncogenes in MAMs and tumor suppressor factors is also important for the development of tumor cells. For example, the p53 protein in MAMs can maintain the activity of the SERCA pump, which is beneficial for maintaining the calcium ion concentration in the ER. When apoptosis is triggered, the ER releases a large number of calcium ions, which enter the mitochondria to cause a calcium ion overload and induce apoptosis. However, in cancer cells, TP53 may be mutated or the p53 protein is inactivated, and thus, the ER cannot maintain a state of relatively high calcium ions, enabling cancer cells to escape apoptosis (Fig. 1).

Stromal interaction molecule 1 (STIM1) is an important calcium sensor located in the ER, which activates ORAI store-operated calcium entry (SOCE) channels. SOCE affects ER calcium content through the activity of calcium-released activated channels (CRAC). CRAC channels are mainly composed of ORAI proteins, which are activated by the ER calcium sensors, stromal interacting proteins or STIMs [36]. In cancer, STIM and ORAI isoforms display increased expression in numerous tumor types and are associated with signaling pathways that positively regulate cancer cell proliferation, migration, invasion, and chemoresistance [37, 38].

Mitochondria and ER stress response

The response of ER to cellular stress is linked to the accumulation of unfolded proteins and called unfolded protein response (UPR). UPR is activated in response to the accumulation of unfolded or misfolded proteins accumulated in the ER. UPR stops protein translation, degrades misfolded proteins, and activates signaling pathways to restore the normal function of cells. As a large number of molecular chaperones assist in the folding of unfolded proteins, they consume a large amount of ATP. Therefore, in order to increase the production of ATP, cells usually increase the contact area between ER and mitochondria, which in turn increases the release of calcium from the ER, causing calcium to flow into mitochondria [63]. If UPR does not reduce cell stress, the ER and mitochondrial contact points resulting from the above process increase, calcium release increases, and mitochondria uptake calcium, leading to apoptosis (Fig. 1).

In cancer cells, UPR is constitutively activated. During tumor development and growth, abnormal cell proliferation requires higher protein synthesis, and cancer cells are subjected to various pressures such as hypoxia, low glucose, low pH, and lack of nutrition, which induce UPR [64]. UPR signaling is initiated by its three mediators: RNA-dependent protein kinase-like kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring enzyme 1α (IRE1α) [65].

PERK in MAMs and MAM-resident PERK were shown to have heterogeneous functions (Fig. 1, Table 1). Hence, only PERK is described below. Activation of PERK signaling and integrated stress response (ISR) is considered a necessary condition for tumor survival under conditions of hypoxia and nutrient deficiency [66]. The activated PERK pathway phosphorylates eukaryotic translation initiation factor 2α (eIF2α). Phosphorylation of eIF2 can be induced by a variety of kinases, including protein kinase R, general control non-repressed 2, and heme-regulated eIF2α kinase. EIF2α phosphorylation-related signaling is described as the ISR. ER oxidoreductase 1α, which regulates ER redox status, is upregulated with PERK signaling. The expression of ER oxidoreductase 1α is significantly increased in various types of cancer [67]. The PERK and ISR signaling pathways may be useful therapeutic targets for cancer. The PERK-specific inhibitor GSK2656157 was reported to inhibit angiogenesis and amino acid metabolism, thus preventing tumorigenesis in vivo [62].

A lack of PERK in MAMs will lead to ER breakage and abnormal calcium release. This functional change in the ER occurs because of the lack of PERK in MAMs. PERK activities have a variety of functions in the ER and MAM. Studies showed that PERK is involved in the adaptation of cancer cells to the challenges of the tumor microenvironment [68,69,70]. Some studies reported the presence of PERK in the ER in tumor cells, but the role of MAM-resident PERK remains unclear [70, 71]. Therefore, MAM-resident PERK may have pathological functions and be a therapeutic target of cancer.

Phospholipid synthesis and transfer between mitochondria and ER

Phospholipids are a major component of all cell membranes, and the ER is the main site of phospholipid synthesis in cells. Phospholipids are normally transported in vesicles to their destination after synthesis in the ER. However, for transport into the mitochondria, phospholipids are directly imported through the membranes [72, 73]. MAMs do not only control the lipid membrane homeostasis of mitochondria and ER but also support the transfer of different lipids and have biological effects on cell fate [74]. A large number of lipid-metabolizing enzymes are abundant in MAMs, where lipid metabolism is also performed [8] (Fig. 1). One manner in which tumor cells inhibit mitochondrial metabolism and apoptosis signals is to alter the ER lipid structure, thus destroying the normal MAM raft.

Phosphatidic acid is converted into phosphatidylserine (PS) in the ER, as the ER contains the relevant enzymes phosphatidylserine synthase 1 (PSS-1) and PSS-2 [75]. The IMM contains PH and SEC7 domain-containing protein 1 (PSD), which converts PS into phosphatidylethanolamine (PE). Therefore, PS must be transferred to the OMM and further transferred to the IMM, where it is converted into PE [75]. The rate-limiting step of PE generation is that PS enters mitochondria through MAMs [75]. Finally, PE returns to the ER, where phosphatidylethanolamine N-methyltransferase 2 (PEMT2) methylates PE to synthesize phosphatidylcholine (PC). However, as mitochondria also contain PC, PC is transferred from the ER into the mitochondria. Therefore, in order to achieve the final lipid composition of both organelles, a large amount of lipid exchange must be performed between these two organelles.

In addition, phosphatidic acid is an important source material for the synthesis of cardiolipin (CL). Phosphatidic acid is transferred from the ER to the OMM and then transferred to the IMM. It is converted into cytidine diphosphate diacylglycerol by the mitochondrial translocator assembly and maintenance protein 41 homolog (Tam41) in the IMM [76]. Next, cytidine diphosphate diacylglycerol further synthesizes glycerol-3-phosphate phosphatase with glyceraldehyde 3-phosphate under the catalysis of phosphatidylglycerophosphate synthase 1; glycerol-3-phosphate phosphatase is dephosphorylated by the phosphatase Gep4 to generate phosphatidylglycerol [77]. Although phosphatidylglycerol is only present in small quantities in the mitochondria, it plays an important role in CL synthesis [78], catalyzed by CL synthase Crd1 [79].

Analysis of the intimal lipid composition of various tumor mitochondria revealed that its cholesterol content was high, and changes in fatty acyl components were observed. Mitochondrial phospholipids in tumor cells are typically shorter than those in normal cells and unsaturated acyl chains are shorter [80, 81]. The composition and content of CL is significantly altered in some tumors [82], which is likely related to defects in CL synthesis and remodeling.

In addition, MAMs contain enzymes that are necessary for cholesterol and ceramide biosynthesis [83, 84]. In hepatocytes, acetyl-CoA acetyltransferase, mitochondrial ACAT1 in the MAM catalyzes the formation of cholesterol esters in the resting state, thereby controlling the balance between membranous and cytoplasmic lipids and low-fat cholesterol. In response to stress, cholesteryl esters are continuously introduced into the mitochondria, and cytochrome P450 initiates steroidogenesis [83]. Ceramide synthetized in the ER flows into the mitochondria and permeabilizes the OMM to apoptotic-inducing proteins, thus initiating apoptosis. MAMS can be considered a specific ceramide pool containing sphingomyelin phosphodiesterase (SMase), ceramide synthase (CerS), and dihydroceramide desaturase (DES). Considering the pro-apoptotic properties of ceramide in the mitochondria, MAM may act as an important reservoir or barrier to prevent the influx of ceramide into the mitochondria.

Cholesterol metabolism is deregulated in carcinogenesis, and cancer cells exhibit increased mitochondrial cholesterol content. Changes in mitochondrial cholesterol transport and metabolism in cancer cells affect the biophysical properties and mitochondrial functions of mitochondrial membranes. Compared to normal cells, the mitochondria of cancer cells are more susceptible to increased cholesterol, which triggers ER stress and apoptosis [85]. Ceramide is considered a tumor suppressor lipid because of its important role in regulating the physiological and drug-induced apoptosis of cells. The production of ceramide under the action of SMase was shown to be important in the regulation of cancer progression. Inhibition of SMase is related to drug resistance to a variety of anticancer drugs [86]. CerS expression was also shown to modulate the sensitivity to cancer chemotherapy drugs and radiotherapy. Overexpression of CerS1 in hek-293 cells was shown to make these cells sensitive to some anticancer drugs, such as cisplatin, carboplatin, doxorubicin, and vincristine.

Mitochondria and peroxisomes

Peroxisomes are ubiquitous and dynamic single membrane-bound organelles in cells, who modulate their numbers, morphology, and activity to adapt to diverse environments in different tissues, organs, and nutritional states [87,88,89]. Peroxisomes play important roles in biosynthesis and signal transduction, including ether-phospholipid biosynthesis, fatty acid α-and β-oxidation, bile acid and docosahexaenoic acid synthesis, glyoxylate metabolism, amino acid catabolism, polyamine oxidation, the metabolism of reactive oxygen and nitrogen species, inflammation, innate immunity, and other processes, which cannot be achieved without interaction with other organelles in the cell [87, 88]. Among them, mitochondria and peroxisomes interact very closely. They cooperate with each other to maintain lipid balance through fatty acid β-oxidation, to maintain the balance of ROS in cells through scavenging, and to resist foreign invasion through antiviral reactions and other immune responses [87,88,89]. In this series of processes, mitochondria and peroxisomes can complete various biological functions through vesicles transport, signaling molecules, and membrane contact sites [90]. They also exhibit a close interplay in generation, fission, proliferation, and degradation [90]. The integrity and stability of peroxisomes are important guarantees for the maintenance of normal mitochondrial function. Peroxisomal dysfunction seriously affects mitochondrial metabolism, morphological stability, and biosynthesis, which directly or indirectly lead to rare genetic diseases, such as X-linked adrenoleukodystrophy, acatalasemia, and Zellweger syndrome, and relatively common age-related disorders, such as diabetes, neurodegenerative disease, and cancer [87, 91].

The connections between the two organelles in biogenesis, degradation, and fission

Mitochondria participate in the formation of peroxisomes. In mammals, peroxisomes can be produced by asymmetric growth and division from pre-existing organelles, as well as by the fusion of pre-peroxisomes from the ER and mitochondria [87, 91], allowing the transport of functional proteins and other compounds from the mitochondria into peroxisomes, which may be one of the reasons why peroxisomes and mitochondria have many similar functions [91] (Fig. 2).

Fig. 2
figure2

The connection between peroxisomes and mitochondria. Mitochondria can communicate with peroxisomes via vesicular transport of MDVs. Key fission components FIS1, MFF, and GDAP1 are shared by both peroxisomes and mitochondria, and they recruit DNM1L to the organelle cleavage site to disrupt organelles. The fatty acid β-oxidation can occur both in mitochondria and peroxisomes. However, the lipid β-oxidation in peroxisomes is not complete, after degrading lipids to medium length, they will be co-transported with acetyl-CoA to the mitochondria for further metabolism. Both mitochondria and peroxisomes can produce ROS, and they are also important organelles for removing ROS and ensuring cell stability. Peroxisomes mainly contain catalase to break down H2O2. ROS are also important signaling molecules, which can induce cell apoptosis

Full size image

The function of mitochondrial and peroxisomal coordination cannot be separated from the transcriptional regulation mechanism, including peroxisome proliferator-activated receptors (PPARs), whose different subtypes have different tissue expression patterns and substrate specificities as well as regulate different target genes [91, 92]. PPARs form a sub-family of nuclear hormone receptors that function as ligand-activated transcription factors to regulate various biological processes [93]. They can regulate the metabolism of cell lipids and carbohydrates, cell differentiation, and tumorigenesis after their activation by ligands that regulate the proliferation of mitochondria and peroxisomes and the expression of lipid β-oxidation related genes [92, 94]. The activity of PPARs is also regulated by many transcriptional coactivators and co-repressors [87, 91]. One coactivator is peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), which is a powerful transcriptional coactivator that modulates physiological and energy homeostatic responses at the transcriptional level in different mammalian tissues and can interact with nuclear receptors to enhance peroxisomal activity and the expression of mitochondrial biosynthetic factors, oxidative phosphorylation subunits, and antioxidant enzymes [95,96,97]. PGC-1α also promotes the generation of peroxisomes in the liver, muscle, and adipose tissues, independently of the effects of PPARs [87, 91]. However, PGC-1α can also induce the generation of peroxisomes in a PPARα-independent manner [97]. In summary, the abundance and activity of mitochondria and peroxisomes are regulated through PPARs and PGC-1α at the transcriptional level (Table 2).

Table 2 The function of related molecules of mitochondria and peroxisomes
Full size table

Both peroxisomes and mitochondria can be generated by fission from pre-existing organelles and share many proteins involved in division [98]. Mitochondrial fission 1 (FIS1) protein, mitochondrial fission factor (MFF), and ganglioside-induced differentiation-associated protein (GDAP) 1, membrane adapter proteins located on the mitochondria and peroxisomes membranes recruit dynamin-1-like protein (DNM1L) to the organelle cleavage site to disrupt organelles through a series of downstream post-transcriptional modifications. Overexpression or downregulation of membrane adaptor proteins induces splitting or elongation these two organelles, respectively [91, 98, 99] (Fig. 2, Table 2).

Dysfunctional and impaired peroxisomes in cells can be cleared by the lysosomal autophagy pathway called pexophagy [100]. The mitochondria are cleared by mutual fusion and phagocytosis by lysosomes called mitophagy [100]. A number of studies have shown that when the peroxisomal function is impaired, mitochondria can exert compensatory effects by increasing their volume through autophagy, but the specific molecular mechanism is not yet clear [91].

The communication mechanisms between the two organelles

Mitochondria and peroxisomes are closely linked through membrane contact sites. In the past, researchers verified the close relationship between the two organelles by studying their spatial structure by using a series of experimental methods [88, 101]. In mammalian cells, mitochondria and peroxisomes contact each other through a complex whose core component is a splice variant of enoyl-CoA isomerase 2, which contains the targeting signals to mediate the close contact between the two organelles [91]. In yeast, peroxin-11, the most abundant peroxisomal membrane protein, is involved in peroxisome generation and composition, which regulates the division of peroxisomal membranes during proliferation [102]. The ER-mitochondrial encounter structure (ERMES) complex serves as a bridge between molecular exchanges and tight links of mitochondria and ER, whereas peroxin-11 binds to the mitochondrial component Mdm34 of the ERMES complex to mediate and promote information transfer between mitochondria and peroxisomes [102] (Fig. 2).

Mitochondria can also communicate with peroxisomes via vesicular transport of mitochondria-derived vesicles [98]. Among them, mitochondrial anchored protein ligase promotes the division of mitochondrial membrane and leads to the formation of vesicles [98, 99]. Next, the mitochondrial vesicles with mitochondrial anchored protein ligase fuse with peroxisomes. This fusion promotes the production of peroxisomes and transports certain specific metabolites and needed proteins to the peroxisomes [98, 99]. In addition, mitochondria and peroxisomes can be linked by the release of biological messengers, including ROS, lipids, or other metabolites, and this process is closely related to the size of the molecules and the permeability of the organelle membranes [87] (Fig. 2).

The metabolic interplay between the two organelles

The β-oxidation of fatty acids occurs simultaneously in the mitochondria and peroxisomes, and each of the β-oxidation cycles involves four consecutive reactions [99]. In these two organelles, the enzymes used for the β-oxidation reaction are different and have different substrate specificities [87]. Dietary fatty acids such as palmitic acid, oleic acid, and linoleic acid are preferentially metabolized in mitochondria, and most carboxylic acid esters such as very-long-chain fatty acids, pristanic acid, other 2-methyl-branched prostanoids, and bile acid intermediates are more likely to be metabolized in peroxisomes [87, 91]. The lipid β-oxidation in peroxisomes is not complete and after oxidizing degradation of lipids to medium length, they are co-transported with oxidatively produced acetyl-CoA to the mitochondria for further metabolism [98, 99]. The acetyl-CoA is used to generate energy in the tricarboxylic acid cycle, and lipids in the mitochondria eventually produce CO2 and H2O [98, 99] (Fig. 2).

Both during the production of ATP in mitochondria and lipid β-oxidation in peroxisomes, ROS is produced, but mitochondria and peroxisomes are also important organelles in removing ROS and ensuring cell stability [103,104,105]. Peroxisomes mainly contain catalase to break down H2O2. When catalase function is altered or its production in peroxisomes is disturbed, it will lead to mitochondrial oxidative stress response and, in severe cases, IMM structure alteration, changes in respiratory chain complex activity, DNA damage, and increased organelle volume, which can further cause oxidative stress damage to the entire cell [105, 106]. Studies have shown that when ROS in peroxisomes exceeds a certain level, ROS level in mitochondria increases, and the redox balance in mitochondria is disturbed, causing mitochondrial breakdown and cell death [104,105,106]. In addition, ROS are important signaling molecules in cells, which can cause mitochondrial and peroxisomal autophagy and apoptosis [107]. When ROS level increases in cells to induce oxidative stress, the expression of starvation-induced protein DEPP is upregulated, which further induces autophagy, thereby protecting cells from injury [108]. Although how mitochondria and peroxisomes communicate through ROS has not been elucidated in detail, it is possibly through intracellular diffusion, potential contact sites, or vesicle trafficking [101] (Fig. 2).

The link between ROS and cancer

Mitochondria and peroxisomes are important organelles in the production and clearance of ROS. Impaired peroxisomal function inevitably leads to an increase in ROS level in mitochondria, which damages the mitochondria and aggravates ROS clearance disorders, thereby promoting the occurrence and development of tumors [103] (Table 2).

ROS as signaling molecules can regulate a variety of physiological and pathological processes [109]. H2O2 is an ROS family member that plays an important role in the signal transduction process of epidermal growth factor (EGF) and platelet-derived growth factor (PDGF). H2O2 can prevent protein-tyrosine phosphatase 1B (PTP1B) from dephosphorylating EGF, thereby promoting EGF stimulation. Additionally, activation of PDGF requires H2O2 to facilitate PDGF-receptor-associated phosphatase and SHP-2 oxidation and inactivation, thereby promoting the signal pathway [110, 111]. PTEN is a negative regulator of the phosphoinositide 3-kinase (PI3K) signaling pathway and a tumor suppressor. Through oxidation and other effects of H2O2, PTEN inhibits the tumor suppressor function and promotes tumor proliferation [110]. ROS production promotes the genomic and chromosomal instability of the cells and mutations in the mitochondrial genome, promoting the production of ROS and signaling pathways in tumors such as PI3K and mitogen-activated protein kinase (MAPK) [110].

ROS production can promote the proliferation and survival of tumor cells under hypoxia conditions. In the absence of oxygen in tumor cells, hypoxia-inducible factors (HIFs), which are transcription factors, are upregulated to promote the expression of oncogenes. Some enzymes, such as prolyl hydroxylases (PHDs), cause degradation of HIFs. However, hypoxia induces an increase in ROS production, preventing the action of PHDs on HIFs, enabling HIFs to promote tumor development [110, 111].

However, ROS function in both normal cells and tumor cells. Some ROS are used as signaling molecules to activate intracellular autophagy and apoptosis pathways, whereas excessive ROS induce cell oxidative stress damage and eventually cell death [112, 113].

In tumor cells, increased metabolic rate, mitochondrial dysfunction, effects of oncogenes, and enhanced intracellular signal transduction lead to increased production of ROS [112]. On the one hand, this increase upregulates the antioxidant system to maintain the stability of the redox reaction in tumor cells; on the other hand, it promotes the development of tumors [112]. ROS promotes cellular DNA damage and genomic instability, and an increase in gene mutation rate easily leads to a malignant phenotype of cells [113]. ROS also induces mitochondrial gene damage and mutation, which further promote tumorigenesis [113]. Besides, ROS further contributes to the proliferation of tumor cells by promoting the function of growth factors and signal transduction [113]. Angiogenesis, invasion, and migration are the final stages of malignant transformation of tumor cells, and ROS promotes tumor angiogenesis by enhancing the expression and activity of vascular endothelial growth factor and hypoxia inducible factor 1α to provide oxygen and nutrition [113]. ROS also mediates the activity of matrix metalloproteinases and Wnt/β-catenin signaling pathways to promote invasion and migration of tumor cells [113], which provides ideas for clinical treatment, such as, reducing ROS production in tumor cells through a series of methods to suppress the occurrence and development of tumors.

However, when the production of ROS in tumor cells exceeds a certain limit, it becomes cytotoxic and reverses the ability of tumor cells to be resistant to chemotherapy [113]. ROS also upregulates the activity of caspase family proteins and death receptor 5 to promote apoptosis, which eventually leads to cell death [113]. A number of studies have shown that PGC1α is upregulated in a variety of tumor cells, which promotes mitochondrial production and the expression of enzymes involved in mitochondrial metabolism [95, 96, 114, 115]. On the one hand, PGC1α can provide more energy for tumor cells by promoting the process of oxidative phosphorylation and the tricarboxylic acid cycle, making tumor cells metabolically superior to normal cells; on the other hand, it can enhance the clearance ability of ROS in tumor cells to protect them from oxidative stress [114,115,116]. However, there are also other reports in the literature that show that the expression of PGC1α is downregulated in some tumors, which may be related to the growth stage and the metabolic conditions of tumor cells [117, 118]. Therefore, upregulation of ROS by specific treatments in tumor cells can also inhibit the tumor growth.

Deficiency and prospects

The interaction between mitochondria and peroxisomes is an important part of maintaining cell stability, and plays an extremely important role in cell metabolism, biosynthesis, and cell fate. Meanwhile, their communication also has an important effect on immune response and resistance of virus infection in host cells. However, many processes have not been researched in detail. For example, the specific details and mechanisms of how mitochondria and peroxisomes communicate through signaling molecules and metabolites, how mitochondrial dysfunction affects peroxisomes and the specific mechanisms of how peroxisome damage affects the mitochondria, and the details of the relationship between mitochondria and peroxisomes in generation are not known. Alteration in the ROS level in peroxisomes will rapidly change the levels in mitochondria; however, how the two interact with each other via a redox mechanism is also unclear. At the same time, in terms of tumor therapy, ROS boosting or ROS scavenging can be applied to the clinic because too much or too little ROS can affect the occurrence and development of tumors. Nowadays, changing ROS level in cells by using pro-oxidants and antioxidants plays an important role in the clinical treatment of tumors cells [113]. Tumor cells have regulatory mechanisms that can adapt to the alteration of redox balance, such as those involving PPARs and PGC-1α, which regulate mitochondria and peroxisomes at the transcriptional level. Effectively destroying this regulatory mechanism will facilitate the treatment of tumors. Therefore, understanding the precise regulatory mechanism between the mitochondria and peroxisomes is the next goal.

Mitochondria and nucleus

As the only organelle possessing an independent genome in the eukaryotic cell, the mitochondrion has its own lifespan in the cell cycle [119, 120]; however, among the more than 1200 mitochondrial proteins, only 13 are encoded by the mitochondrion itself, and most of the mitochondrial proteins are encoded by the nucleus [121]. The mitochondria biogenesis are modulated by the nucleus genome and the mitochondria genome, Therefore, there is a precise and strict regulatory mechanism between the nucleus and mitochondria to control the stability of mitochondria. A dysfunctional crosstalk between these two organelles leads to DNA damage in both the nucleus and mitochondria, calcium overload, and abnormal activation of growth factors [121], as well as metabolism disorders that are hallmarks of carcinoma [122].

Anterograde regulation

The nucleus controls the proteins and information transmitted to the mitochondria by anterograde regulation. Anterograde regulation reflects different stressors through the nuclear genome reprograming which modulate mitochondria biogenesis. The transcription of multiple mitochondrial proteins requires a simple RNA polymerase (POLRMT) and mtDNA transcription factor-Tfam1, Tfb1 m, Tfb2 m, and transcription termination factor (MTERF). Transcriptional control in the mitochondria involves multiple transcription factors and co-activators. Anterograde regulation mainly depends on two set of factors; the first is nuclear respiratory factor 1 (NRF1) and NRF2 which modulate OXPHO genes and mitochondria DNA replication and expression, with NRF1 playing a leading role in this process [123, 124]. By binding to the cytochrome C promoter, NRF1 directly or indirectly regulates mitochondria biogenesis by activating genes related to OXPHO or decreasing other transcription factors such as MEF2A which is related to mitochondria biogenesis. The second set of factors is the PGC family containing PGC1α, PGC1β, and PGC1-like factor, PRC. PGC functions as a co-activator by integrating all physiologic signals and enhancing the function of other transcription factors [125, 126] (Fig. 3c).

Fig. 3
figure3

The mitonuclear communication. a Noncoding RNA in nucleus-mitochondria regulation (using lnc RMRP as an example). The lnc RMRP transcribed in nucleus is translocated in the mitochondria and targets the mtDNA, while the mtDNA encoding small noncoding RNA (snmtRNA) can be transferred to the nucleus. Both processes require the cooperation of RNA-binding proteins such as HuR and GRSF1. b Anterograde regulation. Different cytoplasmic stressors initiate several signaling pathways and activate the same co-activator PGC1α, which subsequently stimulates different transcription factors and nuclear receptors as shown in Fig. 3. The downstream signaling of these transcription factors and nuclear receptors regulates mitochondrial biogenesis. Not all transcription factors, co-activators, and co-repressors are shown in Fig. 3 (see Refs [119, 120]). c Retrograde regulation. Retrograde signaling is triggered by OXPHOS dysfunction and mtDNA defects, which result in the loss of mitochondria potential. The retrograde pathway involves Cn-calcium signaling, AMPK signaling, and activation of molecules such as HnRNP A2, which is a cancer hallmark. Retrograde regulation also increases the expression of certain epigenetic modulators that regulate the nuclear epigenome

Full size image

Nuclear receptors such as PPARs or estrogen-related receptor (ERR) can also initiate anterograde regulation. PPARδ stimulates enzymes involved in fatty acid oxidation, particularly in the heart and muscle tissue, and ERRs modulate the expression of nuclear-encoded-protein in TCA cycle, oxidative phosphorylation (OXPHOS), and the fatty acid oxidation process. The finely tuned regulation of transcription also involves other transcription factors such as CREB, c-myc, and YY1 and co-repressors such as receptor interacting protein 140 (RIP140) to maintain the balance with co-activators. Additionally, chemical modification such as phosphorylation of the transcription factors and/or co-activator/co-repressor occurs during anterograde regulation [127, 128] (Fig. 3c).

The transcriptional control of mitochondria biogenesis is tissue- and organ-specific and different stressors initiate different downstream pathways.

When cells are under stress such as calcium overloading, oxidative pressure, and DNA damage, different stressors activate different downstream cascades, resulting in the activation of different cascades. For example, when ATP production decreases, as observed following exercise and caloric restriction, the rate of AMP/ATP is increased, upregulating the downstream molecules NAD+, sirtuin-1, and PGC1α and promoting mitochondria energy metabolism and biogenesis, whereas calcium overload activates calcium/calmodulin dependent protein kinase type IV or 5′ adenosine monophosphate-activated protein kinase (AMPK) and promote mitochondria biogenesis [119, 129]. By activating specific transcription factors, the nucleus maintains homeostasis in the mitochondria under stress conditions (Fig. 3c).

In addition to activation of multiple stressors, nuclear DNA damage may initiate anterograde regulation. A study showed that nuclear DNA damage triggering anterograde regulation are indispensable in aging [130], which directly upregulates the rate of aging-associated diseases such as neurodegeneration and cancer. The transcriptional alteration of mitochondrial proteins may lead to severe disorders, such as osteosarcoma, breast cancer, and prostate cancer. However, the specific mechanism of anterograde signaling in tumorigenesis has not been widely studied, in contrast to retrograde signaling discussed below.

Retrograde regulation

To maintain a tight cooperation between the mitochondria and nucleus, the mitochondria may also regulate the function of nucleus through retrograde regulation. Loss of the mitochondria membrane potential in the mitochondrial respiratory chain disorders, by DNA mutation or change of the mitochondrial DNA copies [131], initiate the retrograde regulation from mitochondria to the cell nucleus. Many processes in retrograde regulation are considered as markers in tumorigenesis. For example, mtDNA alterations are common in tumorigenesis, and the accumulation of heterogeneous nuclear ribonucleoprotein A2 is a hallmark of cancer. The first confirmed retrograde regulation pathway was found in Saccharomyces cerevisiae and called the RTG-dependent pathway, which involves Rtg1p, Rtg2p, and Rtg3p [132, 133]. When the Rtg1p/Rtg3p complex is activated, it translocates into the nucleus and affects gene transcription. Although only Rtg3p possess a DNA-binding site, the formation of the Rtg1p/Rtg3p complex is still required for the whole process. This process has also a connection with the mammalian target of rapamycin (mTOR) pathway. McKusick-Kaufman syndrome 1 binds to Rtg2, freeing the structural maintenance of 14-3-3 family protein BMH1/2 [134], which removes the inhibition of the Rtg1p/Rtg3p complex. Another study suggest that G protein pathway suppressor 2 may act as Rtg2 in mammalian cells by avoiding the methylation of histone H3k9 [135].

In mammals, retrograde regulation clearly involves the mTOR/AMPK pathway and the mitochondria calcium signaling. As mitochondria are important in calcium buffering, Calcium flows into the cytoplasm from the mitochondria when the mitochondrial function is altered, causing a loss of membrane potential and activating phosphatase calcineurin, which in turn affects gene transcription through nuclear factor-κB and nuclear factor of activated T-cells (Fig. 3b).

Also, the mitochondrial DNA is near to the ROS generation site and has a less sophisticated recovery mechanism, which leads to the mitochondria DNA being more vulnerable under oxidative stress (Fig. 3b).

The mitochondrion OXPHOS and TCA cycle involves genes that easily get damaged in tumorigenesis; however, cancer cells still rely on energy supplied by the mitochondria, in which retrograde signaling plays an important role [1]. Defects in succinate dehydrogenase (SDH) increase succinate levels in the mitochondria, initiating HIF-α signaling and shifting the cell metabolism model from OXPHOS to glycolysis [1, 136]. Defects in fumarate hydratase (FH) increase fumarate levels in mitochondria, which activates NRF2 signaling and increases the expression of heme oxygenase (HMOX1), which is beneficial for forming colonies [1, 137, 138]. Isocitrate dehydrogenase1 (IDH1) and IDH2 disturb the redox status of important transcription factors by preventing the reaction of isocitrate to α-ketoglutarate to stimulate cell proliferation and tumorigenesis [139, 140]. Mutation of all four genes may lead to changes in chromatin methylation and epigenetic modification (Table 3).

Table 3 Retrograde signaling in tumorigenesis
Full size table

Moreover, the mechanism of the epigenetic modification triggered by the mtDNA mutation and alteration of mtDNA copy also connect to some cell metabolism products. The mitochondria satisfy the cell energy demand through the TCA cycle, fatty acid oxidation, and the electron transfer complex, which convert fatty acid and glucose into NADH, acetyl-DNA, and ATP, which can be messenger molecules in modulating the epigenetic modification of the nuclear genome. Therefore, the mitochondria can be an important junction connecting the cell metabolism and cell genome epigenetic modification by regulating the expression of ATP, NAD/NADH, and acetyl-CoA, which are capable of facilitating or inhibiting gene transcription. Studies also show that the mitochondria can influence DNA methylation by regulating the S-adenosyl methionine [121, 141] (Table 3, Fig. 3b).

More importantly, the mtDNA depletion-induced activation of calcium and phosphatase calcineurin (Cn) in the retrograde regulation pathway of mitochondria can lead to genetic and epigenetic changes that are beneficial for apoptosis resistance. The Cn-dependent pathway also participates in epithelial–mesenchymal transition (EMT) in breast cancer and it is induced by the copy number variation of the mitochondrial DNA [142]. EMT is regarded as the major regulator of metastasis, and the reduced mtDNA in human mammary epithelium cell(hMECs) can initiate Cn-dependent mitochondrial retrograde regulation and cause cell polarity loss, which seems like an EMT-like reprogramming, facilitating tumor invasion and migration [143] (Table 3, Fig. 3b).

Noncoding RNA in the communication between the nucleus and mitochondria

Intriguingly, researchers have recently highlighted the important role of noncoding RNA in the communication between the nucleus and mitochondria, as the noncoding RNA nearly covers the whole process of gene transcription and expression. Besides the anterograde and retrograde regulation reviewed above, a study uncovered putative small noncoding RNA encoded by mitochondria genome through the analysis of a small noncoding RNA library of Ruditapes philippinarum. The structure of those small noncoding RNA are close to the microRNA so that the researchers wonder that if the putative small noncoding RNA serve as a potential regulator of the nuclear functionthrough a microRNA-like mechanism [144, 145] (Fig. 3a).

The theory of noncoding RNA as a new regulator in nuclear and mitochondria communication is beginning to emerge; most studies have focused on long noncoding RNA (lncRNA). LncRNA regulates nuclear and mitochondria communication. Nuclear-encoded lncRNA are transmitted into the mitochondria and coordinate mitochondria-induced apoptosis [146, 147], mitochondria metabolism, and mitochondria biogenesis. For instance, ENS-MUST00000136025 stimulates the Bim gene, in turn coordinating mitochondria-induced apoptosis and lncRNA MEG3-induced apoptosis in renal cells by activating the mitochondria pathway [146]. In contrast, lncRNA encoded by the mitochondria modulate nuclear genome reprogramming. The mitochondria genome-encoded lncRNAs are classified into three groups: (1) lnc5, lnc6; (2) chimeric mitochondria-encoded lnRNA; (3) putative mitochondria-encoded lnRNA. Propagation of the lncRNA from the nucleus to the mitochondria requires the cooperation of RNA-binding proteins such as human antigen R protein (HuR), G-rich RNA sequence-binding factor 1 (GRSF1), and SMRT/HDAC-associated repressor protein (SHARP) [148]; however, the specific mechanism of the transportation of noncoding RNA from the nucleus to the mitochondria is unclear (Fig. 3a).

MicroRNAs are also vital in the interplay between the two organelles. For example, miR181c directly enters the mitochondria and affects the transcription of its target gene, while miR663 affects OXPHOS in the mitochondria and accelerates carcinoma by downregulating the expression of ubiquinol-cytochrome c reductase complex assembly factor 2 [149]. has-miR4485 is transcribed in the nucleus and resides in the mitochondria; this miRNA binds mitochondria 16 s rRNA to reduce tumorigenesis in breast cancer cells (Table 4).

Table 4 Noncoding RNA in nuclei and mitochondria interaction
Full size table

The functions of noncoding RNAs in nuclear and mitochondria communication in tumorigenesis are unclear. Based on their specific mechanisms of action, further studies should focus on identifying the targets of certain noncoding RNAs to determine their roles in tumorigenesis.

Conclusion

The mitochondria are the Achill’s hell of malignancy, especially when recent studies shows the complex connection between the mitochondria and cancer, especially the cancer metabolism. The cancer cells do not just rely on the dysfunction state of mitochondria like the “Warburg effect” suggest but manipulate the mitochondria and turn it into its energy factory through the mechanisms mentioned before, such as the HIF-αsignaling in the retrograde regulation. However, there are still numerous mystery of the role that mitochondria might play in tumorigenesis to be solved, for example, the specific mechanism of mtDNA mutation and defects in tumorigenesis. Despite the metabolism angle that we used to visualize the mitochondria in cancer, the organelle interplay may offer a new clue for further exploration in clinical drug design and development.

Currently, we study the cell as a whole and not as a mix of different organelles. Researchers are realizing that organelles are communicating and maintaining the cell homeostasis through their tight connection. It is universally acknowledged that the mitochondrion is the major source of energy, and its importance cannot be disputed. Therefore, it is indispensable for us to explore the interplay between the mitochondria and other organelles. As elaborated above in this review, understanding the communication between mitochondria and the ER, peroxisome and nucleus is necessary in terms of understanding the role that mitochondria play in tumorigenesis.

The mitochondria in cancer involves the pathways like the PI3 K pathway, P53 pathway, calcium related pathway etc. which are important in cell metabolism, cell proliferation, mitochondria induced cell apoptosis and so on. We regard the mitochondria a decent target in cancer treatment for the reason that the mitochondria is pivotal in the cell cycle.

Ongoing clinical trials and drug development are mainly focusing on the metabolism mechanism such as electron transport chain, TCA cycle and the Oxidative phosphorylation. Other drugs also target at the calcium buffering the signaling pathways involved in this communication.

The mitochondria are a rather multifunctional organelle; hence, considering a single mechanism or focusing on a single target can be counterproductive. For example, the use of pro-oxidants to destroy the redox balance in tumor cells promotes cell death, but it also increases the risk of normal cell canceration. The use of antioxidants reduces intracellular ROS in tumor cells, thereby weakening their mutation and invasive ability, but it also attenuates the ability of ROS to induce cell injury and apoptosis, which promotes tumor development to a certain degree.

However, studies on organelle communication are limited. Cancer exhibits great heterogeneity, and thus, it is unclear whether mechanisms involved in tumor cells occur in other tissues and/or organs. Moreover, recent studies have focused on the molecular level, and thus, further investigations are needed using animal models, which would be more significant for clinical application and drug development.

Therefore, considering the complexity of organelle interaction, there are still unknown molecular mechanisms that warrant further exploration.

Abbreviations

TCA:

tricarboxylic acid

MAMs:

mitochondria-associated ER membranes

IP3R:

inositol 1,4,5 trisphosphate receptor

VDACs:

voltage-dependent anion channels

OMM:

outer mitochondrial membrane

MCU:

mitochondrial calcium uniporter

IMM:

inner mitochondrial membrane

GRP-75:

glucose regulated protein 75

MFN2:

mitofusin 2

PTEN:

phosphatase and tensin homolog on chromosome 10

PML:

promyelocytic leukemia

Bcl2-L-10:

Bcl-2-like protein 10

IRBIT:

IP3Rs binding protein released with IP3

SERCA:

sarco/endoplasmic reticulum calcium ATPase

STIM:

stromal interaction molecule 1

SOCE:

store-operated calcium entry

CRAC:

calcium-released activated channels

UPR:

unfolded protein response

PERK:

RNA-dependent protein kinase-like kinase

ATF6:

activating transcription factor 6

IRE1α:

inositol-requiring enzyme 1α

eIF2α:

eukaryotic translation initiation factor 2α

ISR:

integrated stress response

PS:

phosphatidylserine

PE:

phosphatidylethanolamine

PC:

phosphatidylcholine

CL:

cardiolipin

PSD:

PH and SEC7 domain-containing protein

SMase:

sphingomyelin phosphodiesterase

CerS:

ceramide synthase

DES:

dihydroceramide desaturase

PPARs:

peroxisome proliferator-activated receptors

PGC-1:

αphosphatidylglycerol

FIS1:

mitochondrial fission 1 protein

DNM1L:

dynamin-1-like protein

GDAP:

differentiation-associated protein

MFF:

mitochondrial fission factor

ERMES:

ER-mitochondrial encounter structure

EGF:

epidermal growth factor

PDGF:

platelet-derived growth factor

PTP1B:

protein-tyrosine phosphatase 1B

PI3K:

phosphoinositide 3-kinase

MAPK:

mitogen-activated protein kinase

HIFs:

hypoxia-inducible factors

PHDs:

prolyl hydroxylases

OXPHOS:

oxidative phosphorylation

snmtRNA:

mtDNA encoded small noncoding RNA

POLRMT:

RNA polymerase

MTERF:

transcription termination factor

NRF1:

nuclear respiratory factor 1

ERR:

estrogen related receptor

RIP140:

receptor interacting protein 140

AMPK:

5′ adenosine monophosphate-activated protein kinase

mTOR:

mammalian target of rapamycin

Cn:

calcineurin

SDH:

succinate dehydrogenase

FH:

fumarate hydratase

HMOX1:

haem oxygenase I

DH1:

isocitrate dehydrogenase 1

EMT:

epithelial–mesenchymal transition

hMECs:

human mammary epithelium cell

lncRNA:

long noncoding RNA

HuR:

human antigen R protein

GRSF1:

G-rich RNA sequence-binding factor 1

SHARP:

SMRT/HDAC associated repressor protein

References

  1. 1.

    Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12:685–98.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  2. 2.

    Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Deng H, Cao K, Zhou M, Xiang B, Li X, Li Y, Li G, Xiong W, Zeng Z. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  3. 3.

    Lezi E, Swerdlow RH. Mitochondria in neurodegeneration. Adv Exp Med Biol. 2012;942:269–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. 4.

    Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–59.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;106–107:17–32.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  6. 6.

    Giacomello M, Pellegrini L. The coming of age of the mitochondria-ER contact: a matter of thickness. Cell Death Differ. 2016;23:1417–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. Biochim Biophys Acta. 1837;2014:461–9.

    Google Scholar 

  8. 8.

    Raturi A, Simmen T. Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM). Biochim Biophys Acta. 1833;2013:213–24.

    Google Scholar 

  9. 9.

    Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak Y, Bao XR, Strittmatter L, Goldberger O, Bogorad RL, Koteliansky V, Mootha VK. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature. 2011;476:341–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Chaudhuri D, Sancak Y, Mootha VK, Clapham DE. MCU encodes the pore conducting mitochondrial calcium currents. Elife. 2013;2:e00704.

    PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Morciano G, Marchi S, Morganti C, Sbano L, Bittremieux M, Kerkhofs M, Corricelli M, Danese A, Karkucinska-Wieckowska A, Wieckowski MR, Bultynck G, Giorgi C, Pinton P. Role of mitochondria-associated ER membranes in calcium regulation in cancer-specific settings. Neoplasia. 2018;20:510–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Berridge MJ. The inositol trisphosphate/calcium signaling pathway in health and disease. Physiol Rev. 2016;96:1261–96.

    CAS  PubMed  Article  Google Scholar 

  13. 13.

    Csordas G, Varnai P, Golenar T, Roy S, Purkins G, Schneider TG, Balla T, Hajnoczky G. Imaging interorganelle contacts and local calcium dynamics at the ER-mitochondrial interface. Mol Cell. 2010;39:121–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, Balla T, Mannella CA, Hajnoczky G. Structural and functional features and significance of the physical linkage between ER and mitochondria. J Cell Biol. 2006;174:915–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    de Brito OM, Scorrano L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature. 2008;456:605–10.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Naon D, Zaninello M, Giacomello M, Varanita T, Grespi F, Lakshminaranayan S, Serafini A, Semenzato M, Herkenne S, Hernandez-Alvarez MI, Zorzano A, De Stefani D, Dorn GW 2nd, Scorrano L. Critical reappraisal confirms that Mitofusin 2 is an endoplasmic reticulum-mitochondria tether. Proc Natl Acad Sci U S A. 2016;113:11249–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Filadi R, Greotti E, Turacchio G, Luini A, Pozzan T, Pizzo P. Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria coupling. Proc Natl Acad Sci U S A. 2015;112:E2174–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, Cavagna D, Nagy AI, Balla T, Rizzuto R. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol. 2006;175:901–11.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer. 2017;17:367–80.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, Zhang S, Gong Z, Wei F, Yang L, He Y, Zhou M, Li X, Li G, Xiong W, Zeng Z. Role of long non-coding RNAs in glucose metabolism in cancer. Mol Cancer. 2017;16:130.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  21. 21.

    Prole DL, Taylor CW. Inositol 1,4,5-trisphosphate receptors and their protein partners as signalling hubs. J Physiol. 2016;594:2849–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Szado T, Vanderheyden V, Parys JB, De Smedt H, Rietdorf K, Kotelevets L, Chastre E, Khan F, Landegren U, Soderberg O, Bootman MD, Roderick HL. Phosphorylation of inositol 1,4,5-trisphosphate receptors by protein kinase B/Akt inhibits Ca2+ release and apoptosis. Proc Natl Acad Sci U S A. 2008;105:2427–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13:283–96.

    CAS  PubMed  Article  Google Scholar 

  24. 24.

    Missiroli S, Bonora M, Patergnani S, Poletti F, Perrone M, Gafa R, Magri E, Raimondi A, Lanza G, Tacchetti C, Kroemer G, Pandolfi PP, Pinton P, Giorgi C. PML at mitochondria-associated membranes is critical for the repression of autophagy and cancer development. Cell Rep. 2016;16:2415–27.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Marchi S, Marinello M, Bononi A, Bonora M, Giorgi C, Rimessi A, Pinton P. Selective modulation of subtype III IP(3)R by Akt regulates ER Ca(2)(+) release and apoptosis. Cell Death Dis. 2012;3:e304.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Wang YA, Li XL, Mo YZ, Fan CM, Tang L, Xiong F, Guo C, Xiang B, Zhou M, Ma J, Huang X, Wu X, Li Y, Li GY, Zeng ZY, Xiong W. Effects of tumor metabolic microenvironment on regulatory T cells. Mol Cancer. 2018;17:168.

    PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Plevova P, Bouchal J, Fiuraskova M, Foretova L, Navratilova M, Zapletalova J, Curik R, Kubala O, Prokop J, Kolar Z. PML protein expression in hereditary and sporadic breast cancer. Neoplasma. 2007;54:263–8.

    CAS  PubMed  Google Scholar 

  28. 28.

    Vervloessem T, Kerkhofs M, La Rovere RM, Sneyers F, Parys JB, Bultynck G. Bcl-2 inhibitors as anti-cancer therapeutics: the impact of and on calcium signaling. Cell Calcium. 2018;70:102–16.

    CAS  PubMed  Article  Google Scholar 

  29. 29.

    Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47–59.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Lian Y, Xiong F, Yang L, Bo H, Gong Z, Wang Y, Wei F, Tang Y, Li X, Liao Q, Wang H, Zhou M, Xiang B, Wu X, Li Y, Li X, Chen X, Li G, Guo C, Zeng Z, Xiong W. Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway. J Exp Clin Cancer Res. 2018;37:253.

    PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Rong YP, Bultynck G, Aromolaran AS, Zhong F, Parys JB, De Smedt H, Mignery GA, Roderick HL, Bootman MD, Distelhorst CW. The BH4 domain of Bcl-2 inhibits ER calcium release and apoptosis by binding the regulatory and coupling domain of the IP3 receptor. Proc Natl Acad Sci U S A. 2009;106:14397–402.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Monaco G, Decrock E, Arbel N, van Vliet AR, La Rovere RM, De Smedt H, Parys JB, Agostinis P, Leybaert L, Shoshan-Barmatz V, Bultynck G. The BH4 domain of anti-apoptotic Bcl-XL, but not that of the related Bcl-2, limits the voltage-dependent anion channel 1 (VDAC1)-mediated transfer of pro-apoptotic Ca2+ signals to mitochondria. J Biol Chem. 2015;290:9150–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Bonneau B, Ando H, Kawaai K, Hirose M, Takahashi-Iwanaga H, Mikoshiba K. IRBIT controls apoptosis by interacting with the Bcl-2 homolog, Bcl2l10, and by promoting ER-mitochondria contact. Elife. 2016;5:e19896.

    PubMed  PubMed Central  Article  Google Scholar 

  34. 34.

    Vandecaetsbeek I, Vangheluwe P, Raeymaekers L, Wuytack F, Vanoevelen J. The Ca2+ pumps of the endoplasmic reticulum and Golgi apparatus. Cold Spring Harb Perspect Biol. 2011;3:a004184.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  35. 35.

    Lynes EM, Bui M, Yap MC, Benson MD, Schneider B, Ellgaard L, Berthiaume LG, Simmen T. Palmitoylated TMX and calnexin target to the mitochondria-associated membrane. EMBO J. 2012;31:457–70.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Smyth JT, Hwang SY, Tomita T, DeHaven WI, Mercer JC, Putney JW. Activation and regulation of store-operated calcium entry. J Cell Mol Med. 2010;14:2337–49.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Wei F, Wu Y, Tang L, He Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Liao Q, Zhang W, Zhou M, Xiang B, Li X, Li Y, Li G, Xiong W, Zeng Z. BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. Br J Cancer. 2018;118:233–47.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. Cancer Cell. 2009;15:124–34.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Khan MT, Wagner L 2nd, Yule DI, Bhanumathy C, Joseph SK. Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J Biol Chem. 2006;281:3731–7.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Zinda MJ, Johnson MA, Paul JD, Horn C, Konicek BW, Lu ZH, Sandusky G, Thomas JE, Neubauer BL, Lai MT, Graff JR. AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. Clin Cancer Res. 2001;7:2475–9.

    CAS  PubMed  Google Scholar 

  41. 41.

    Gonzalez-Angulo AM, Krop I, Akcakanat A, Chen H, Liu S, Li Y, Culotta KS, Tarco E, Piha-Paul S, Moulder-Thompson S, Velez-Bravo V, Sahin AA, Doyle LA, Do KA, Winer EP, Mills GB, Kurzrock R, Meric-Bernstam F. SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer. J Natl Cancer Inst. 2015;107:p.dju493.

    Article  CAS  Google Scholar 

  42. 42.

    White C, Li C, Yang J, Petrenko NB, Madesh M, Thompson CB, Foskett JK. The endoplasmic reticulum gateway to apoptosis by Bcl-X(L) modulation of the InsP3R. Nat Cell Biol. 2005;7:1021–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  43. 43.

    Pinton P, Ferrari D, Magalhaes P, Schulze-Osthoff K, Di Virgilio F, Pozzan T, Rizzuto R. Reduced loading of intracellular Ca(2+) stores and downregulation of capacitative Ca(2+) influx in Bcl-2-overexpressing cells. J Cell Biol. 2000;148:857–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Xie Q, Su J, Jiao B, Shen L, Ma L, Qu X, Yu C, Jiang X, Xu Y, Sun L. ABT737 reverses cisplatin resistance by regulating ER-mitochondria Ca2+ signal transduction in human ovarian cancer cells. Int J Oncol. 2016;49:2507–19.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Fan Z, Yu H, Cui N, Kong X, Liu X, Chang Y, Wu Y, Sun L, Wang G. ABT737 enhances cholangiocarcinoma sensitivity to cisplatin through regulation of mitochondrial dynamics. Exp Cell Res. 2015;335:68–81.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther. 2010;332:388–97.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Dorn GW 2nd, Song M, Walsh K. Functional implications of mitofusin 2-mediated mitochondrial-SR tethering. J Mol Cell Cardiol. 2015;78:123–8.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Schneeberger M, Dietrich MO, Sebastian D, Imbernon M, Castano C, Garcia A, Esteban Y, Gonzalez-Franquesa A, Rodriguez IC, Bortolozzi A, Garcia-Roves PM, Gomis R, Nogueiras R, Horvath TL, Zorzano A, Claret M. Mitofusin 2 in POMC neurons connects ER stress with leptin resistance and energy imbalance. Cell. 2013;155:172–87.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Munoz JP, Ivanova S, Sanchez-Wandelmer J, Martinez-Cristobal P, Noguera E, Sancho A, Diaz-Ramos A, Hernandez-Alvarez MI, Sebastian D, Mauvezin C, Palacin M, Zorzano A. Mfn2 modulates the UPR and mitochondrial function via repression of PERK. EMBO J. 2013;32:2348–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  50. 50.

    Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, Bononi A, Bonora M, Duszynski J, Bernardi R, Rizzuto R, Tacchetti C, Pinton P, Pandolfi PP. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science. 2010;330:1247–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. 51.

    Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. Embo J. 2012;31:4106–23.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Lei M, Wang X, Ke Y, Solaro RJ. Regulation of Ca(2 +) transient by PP2A in normal and failing heart. Front Physiol. 2015;6:13.

    PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O’Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma’ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G. Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest. 2017;127:2081–90.

    PubMed  PubMed Central  Article  Google Scholar 

  54. 54.

    Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, Pandolfi PP, Pinton P. Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. Cell Death Differ. 2013;20:1631–43.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  55. 55.

    Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387–90.

    PubMed  Article  Google Scholar 

  56. 56.

    Liu H, Feng X, Ennis KN, Behrmann CA, Sarma P, Jiang TT, Kofuji S, Niu L, Stratton Y, Thomas HE, Yoon SO, Sasaki AT, Plas DR. Pharmacologic Targeting of S6K1 in PTEN-Deficient Neoplasia. Cell Rep. 2017;18:2088–95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. 57.

    Giorgi C, Bonora M, Sorrentino G, Missiroli S, Poletti F, Suski JM, Galindo Ramirez F, Rizzuto R, Di Virgilio F, Zito E, Pandolfi PP, Wieckowski MR, Mammano F, Del Sal G, Pinton P. p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+ -dependent manner. Proc Natl Acad Sci U S A. 2015;112:1779–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Wei F, Jing YZ, He Y, Tang YY, Yang LT, Wu YF, Tang L, Shi L, Gong ZJ, Guo C, Zhou M, Xiang B, Li XL, Li Y, Li GY, Xiong W, Zeng ZY, Xiong F. Cloning and characterization of the putative AFAP1-AS1 promoter region. J Cancer. 2019;10:1145–53.

    PubMed  PubMed Central  Article  Google Scholar 

  59. 59.

    Xiong F, Deng S, Huang HB, Li XY, Zhang WL, Liao QJ, Ma J, Li XL, Xiong W, Li GY, Zeng ZY, Guo C. Effects and mechanisms of innate immune molecules on inhibiting nasopharyngeal carcinoma. Chin Med J (Engl). 2019;132:749–52.

    PubMed  Article  Google Scholar 

  60. 60.

    Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuypere JP, Piette J, Linehan C, Gupta S, Samali A, Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. Cell Death Differ. 2012;19:1880–91.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. 61.

    Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, Grant SW, Li WH, Heerding DA, Minthorn E, Mencken T, Atkins C, Liu Q, Rabindran S, Kumar R, Hong X, Goetz A, Stanley T, Taylor JD, Sigethy SD, Tomberlin GH, Hassell AM, Kahler KM, Shewchuk LM, Gampe RT. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J Med Chem. 2012;55:7193–207.

    CAS  PubMed  Article  Google Scholar 

  62. 62.

    Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, Choudhry AE, Alsaid H, Jucker BM, Axten JM, Kumar R. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Can Res. 2013;73:1993–2002.

    CAS  Article  Google Scholar 

  63. 63.

    Bravo R, Gutierrez T, Paredes F, Gatica D, Rodriguez AE, Pedrozo Z, Chiong M, Parra V, Quest AF, Rothermel BA, Lavandero S. Endoplasmic reticulum: ER stress regulates mitochondrial bioenergetics. Int J Biochem Cell Biol. 2012;44:16–20.

    CAS  PubMed  Article  Google Scholar 

  64. 64.

    Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, Wang Y, Xiong F, Guo C, Li Y, Li X, Li G, Zeng Z, Xiong W, Wang F. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18:29.

    PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, Wu X, Ma J, Zhou M, Li X, Li Y, Li G, Xiong W, Guo C, Zeng Z. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.

    PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Clarke HJ, Chambers JE, Liniker E, Marciniak SJ. Endoplasmic reticulum stress in malignancy. Cancer Cell. 2014;25:563–73.

    CAS  PubMed  Article  Google Scholar 

  67. 67.

    Kutomi G, Tamura Y, Tanaka T, Kajiwara T, Kukita K, Ohmura T, Shima H, Takamaru T, Satomi F, Suzuki Y, Torigoe T, Sato N, Hirata K. Human endoplasmic reticulum oxidoreductin 1-alpha is a novel predictor for poor prognosis of breast cancer. Cancer Sci. 2013;104:1091–6.

    CAS  PubMed  Article  Google Scholar 

  68. 68.

    Bo H, Fan L, Li J, Liu Z, Zhang S, Shi L, Guo C, Li X, Liao Q, Zhang W, Zhou M, Xiang B, Li X, Li G, Xiong W, Zeng Z, Xiong F, Gong Z. High expression of lncRNA AFAP1-AS1 promotes the progression of colon cancer and predicts poor prognosis. J Cancer. 2018;9:4677–83.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Bu Y, Diehl JA. PERK Integrates Oncogenic Signaling and Cell Survival During Cancer Development. J Cell Physiol. 2016;231:2088–96.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Hou X, Liu Y, Liu H, Chen X, Liu M, Che H, Guo F, Wang C, Zhang D, Wu J, Chen X, Shen C, Li C, Peng F, Bi Y, Yang Z, Yang G, Ai J, Gao X, Zhao S. PERK silence inhibits glioma cell growth under low glucose stress by blockage of p-AKT and subsequent HK2’s mitochondria translocation. Sci Rep. 2015;5:9065.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Nagelkerke A, Bussink J, Mujcic H, Wouters BG, Lehmann S, Sweep FC, Span PN. Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. Breast Cancer Res. 2013;15:R2.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  72. 72.

    Prinz WA. Lipid trafficking sans vesicles: where, why, how? Cell. 2010;143:870–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  73. 73.

    Schlattner U, Tokarska-Schlattner M, Rousseau D, Boissan M, Mannella C, Epand R, Lacombe ML. Mitochondrial cardiolipin/phospholipid trafficking: the role of membrane contact site complexes and lipid transfer proteins. Chem Phys Lipids. 2014;179:32–41.

    CAS  PubMed  Article  Google Scholar 

  74. 74.

    van Vliet AR, Verfaillie T, Agostinis P. New functions of mitochondria associated membranes in cellular signaling. Biochim Biophys Acta. 1843;2014:2253–62.

    Google Scholar 

  75. 75.

    Vance JE. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. Biochim Biophys Acta. 1841;2014:595–609.

    Google Scholar 

  76. 76.

    Tamura Y, Harada Y, Nishikawa S, Yamano K, Kamiya M, Shiota T, Kuroda T, Kuge O, Sesaki H, Imai K, Tomii K, Endo T. Tam41 is a CDP-diacylglycerol synthase required for cardiolipin biosynthesis in mitochondria. Cell Metab. 2013;17:709–18.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  77. 77.

    Osman C, Haag M, Wieland FT, Brugger B, Langer T. A mitochondrial phosphatase required for cardiolipin biosynthesis: the PGP phosphatase Gep4. EMBO J. 2010;29:1976–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Mejia EM, Hatch GM. Mitochondrial phospholipids: role in mitochondrial function. J Bioenerg Biomembr. 2016;48:99–112.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Jiang F, Ryan MT, Schlame M, Zhao M, Gu Z, Klingenberg M, Pfanner N, Greenberg ML. Absence of cardiolipin in the crd1 null mutant results in decreased mitochondrial membrane potential and reduced mitochondrial function. J Biol Chem. 2000;275:22387–94.

    CAS  PubMed  Article  Google Scholar 

  80. 80.

    Deng X, Xiong F, Li X, Xiang B, Li Z, Wu X, Guo C, Li X, Li Y, Li G, Xiong W, Zeng Z. Application of atomic force microscopy in cancer research. J Nanobiotechnology. 2018;16:102.

    PubMed  PubMed Central  Article  Google Scholar 

  81. 81.

    Fan C, Tang Y, Wang J, Xiong F, Guo C, Wang Y, Xiang B, Zhou M, Li X, Wu X, Li Y, Li X, Li G, Xiong W, Zeng Z. The emerging role of Epstein-Barr virus encoded microRNAs in nasopharyngeal carcinoma. J Cancer. 2018;9:2852–64.

    PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Kiebish MA, Han X, Cheng H, Chuang JH, Seyfried TN. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res. 2008;49:2545–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  83. 83.

    Fujimoto M, Hayashi T, Su TP. The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria. Biochem Biophys Res Commun. 2012;417:635–9.

    CAS  PubMed  Article  Google Scholar 

  84. 84.

    Issop L, Fan J, Lee S, Rone MB, Basu K, Mui J, Papadopoulos V. Mitochondria-associated membrane formation in hormone-stimulated Leydig cell steroidogenesis: role of ATAD3. Endocrinology. 2015;156:334–45.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  85. 85.

    Sbiera S, Leich E, Liebisch G, Sbiera I, Schirbel A, Wiemer L, Matysik S, Eckhardt C, Gardill F, Gehl A, Kendl S, Weigand I, Bala M, Ronchi CL, Deutschbein T, Schmitz G, Rosenwald A, Allolio B, Fassnacht M, Kroiss M. Mitotane inhibits sterol-O-acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015;156:3895–908.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  86. 86.

    Adada M, Luberto C, Canals D. Inhibitors of the sphingomyelin cycle: sphingomyelin synthases and sphingomyelinases. Chem Phys Lipids. 2016;197:45–59.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  87. 87.

    Schrader M, Costello J, Godinho LF, Islinger M. Peroxisome-mitochondria interplay and disease. J Inherit Metab Dis. 2015;38:681–702.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  88. 88.

    Cohen Y, Klug YA, Dimitrov L, Erez Z, Chuartzman SG, Elinger D, Yofe I, Soliman K, Gartner J, Thoms S, Schekman R, Elbaz-Alon Y, Zalckvar E, Schuldiner M. Peroxisomes are juxtaposed to strategic sites on mitochondria. Mol BioSyst. 2014;10:1742–8.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  89. 89.

    Hosoi KI, Miyata N, Mukai S, Furuki S, Okumoto K, Cheng EH, Fujiki Y. The VDAC2-BAK axis regulates peroxisomal membrane permeability. J Cell Biol. 2017;216:709–22.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L, Xiong F, Zhang S, Gong Z, Nie S, Liao Q, Li X, Li X, Li Y, Li G, Zeng Z, Xiong W, Guo C. LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis. Mol Cancer. 2018;17:77.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  91. 91.

    Fransen M, Lismont C, Walton P. The peroxisome-mitochondria connection: how and why? Int J Mol Sci. 2017;18:1126.

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  92. 92.

    Niu Z, Shi Q, Zhang W, Shu Y, Yang N, Chen B, Wang Q, Zhao X, Chen J, Cheng N, Feng X, Hua Z, Ji J, Shen P. Caspase-1 cleaves PPARgamma for potentiating the pro-tumor action of TAMs. Nat Commun. 2017;8:766.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  93. 93.

    Monsalve FA, Pyarasani RD, Delgado-Lopez F, Moore-Carrasco R. Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm. 2013;2013:549627.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  94. 94.

    Patterson AD, Shah YM, Matsubara T, Krausz KW, Gonzalez FJ. Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity. Hepatology. 2012;56:281–90.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  95. 95.

    Luo C, Lim JH, Lee Y, Granter SR, Thomas A, Vazquez F, Widlund HR, Puigserver P. A PGC1alpha-mediated transcriptional axis suppresses melanoma metastasis. Nature. 2016;537:422–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  96. 96.

    Fan J, Li X, Issop L, Culty M, Papadopoulos V. ACBD2/ECI2-mediated peroxisome-mitochondria interactions in leydig cell steroid biosynthesis. Mol Endocrinol. 2016;30:763–82.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  97. 97.

    Huang TY, Zheng D, Houmard JA, Brault JJ, Hickner RC, Cortright RN. Overexpression of PGC-1alpha increases peroxisomal activity and mitochondrial fatty acid oxidation in human primary myotubes. Am J Physiol Endocrinol Metab. 2017;312:E253–63.

    PubMed  PubMed Central  Article  Google Scholar 

  98. 98.

    Mohanty A, McBride HM. Emerging roles of mitochondria in the evolution, biogenesis, and function of peroxisomes. Front Physiol. 2013;4:268.

    PubMed  PubMed Central  Article  Google Scholar 

  99. 99.

    Thoms S, Gronborg S, Gartner J. Organelle interplay in peroxisomal disorders. Trends Mol Med. 2009;15:293–302.

    CAS  PubMed  Article  Google Scholar 

  100. 100.

    Schonenberger MJ, Kovacs WJ. Hypoxia signaling pathways: modulators of oxygen-related organelles. Front Cell Dev Biol. 2015;3:42.

    PubMed  PubMed Central  Article  Google Scholar 

  101. 101.

    Shai N, Schuldiner M, Zalckvar E. No peroxisome is an island—peroxisome contact sites. Biochem Biophys Acta. 1863;2016:1061–9.

    Google Scholar 

  102. 102.

    Mattiazzi Usaj M, Brloznik M, Kaferle P, Zitnik M, Wolinski H, Leitner F, Kohlwein SD, Zupan B, Petrovic U. Genome-wide localization study of yeast Pex11 identifies peroxisome-mitochondria interactions through the ERMES complex. J Mol Biol. 2015;427:2072–87.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  103. 103.

    Dai DF, Chiao YA, Martin GM, Marcinek DJ, Basisty N, Quarles EK, Rabinovitch PS. Mitochondrial-targeted catalase: extended longevity and the roles in various disease models. Prog Mol Biol Transl Sci. 2017;146:203–41.

    PubMed  Article  Google Scholar 

  104. 104.

    Tang Y, Wang J, Lian Y, Fan C, Zhang P, Wu Y, Li X, Xiong F, Li X, Li G, Xiong W, Zeng Z. Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer. Mol Cancer. 2017;16:42.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  105. 105.

    Walker CL, Pomatto LCD, Tripathi DN, Davies KJA. Redox regulation of homeostasis and proteostasis in peroxisomes. Physiol Rev. 2018;98:89–115.

    CAS  PubMed  Article  Google Scholar 

  106. 106.

    Wei F, Tang L, He Y, Wu Y, Shi L, Xiong F, Gong Z, Guo C, Li X, Liao Q, Zhang W, Ni Q, Luo J, Li X, Li Y, Peng C, Chen X, Li G, Xiong W, Zeng Z. BPIFB1 (LPLUNC1) inhibits radioresistance in nasopharyngeal carcinoma by inhibiting VTN expression. Cell Death Dis. 2018;9:432.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  107. 107.

    Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, Zeng Z, Xiong W. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  108. 108.

    Salcher S, Hermann M, Kiechl-Kohlendorfer U, Ausserlechner MJ, Obexer P. C10ORF10/DEPP-mediated ROS accumulation is a critical modulator of FOXO3-induced autophagy. Mol Cancer. 2017;16:95.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  109. 109.

    Reczek CR, Chandel NS. ROS-dependent signal transduction. Curr Opin Cell Biol. 2015;33:8–13.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  110. 110.

    Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  111. 111.

    Diebold L, Chandel NS. Mitochondrial ROS regulation of proliferating cells. Free Radic Biol Med. 2016;100:86–93.

    CAS  PubMed  Article  Google Scholar 

  112. 112.

    He Y, Jing Y, Wei F, Tang Y, Yang L, Luo J, Yang P, Ni Q, Pang J, Liao Q, Xiong F, Guo C, Xiang B, Li X, Zhou M, Li Y, Xiong W, Zeng Z, Li G. Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma. Cell Death Dis. 2018;9:235.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  113. 113.

    Raza MH, Siraj S, Arshad A, Waheed U, Aldakheel F, Alduraywish S, Arshad M. ROS-modulated therapeutic approaches in cancer treatment. J Cancer Res Clin Oncol. 2017;143:1789–809.

    CAS  PubMed  Article  Google Scholar 

  114. 114.

    Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, Puigserver P. PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23:287–301.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  115. 115.

    Tan Z, Luo X, Xiao L, Tang M, Bode AM, Dong Z, Cao Y. The Role of PGC1alpha in cancer metabolism and its therapeutic implications. Mol Cancer Ther. 2016;15:774–82.

    CAS  PubMed  Article  Google Scholar 

  116. 116.

    Luo C, Widlund HR, Puigserver P. PGC-1 coactivators: shepherding the mitochondrial biogenesis of tumors. Trends Cancer. 2016;2:619–31.

    PubMed  PubMed Central  Article  Google Scholar 

  117. 117.

    Wei F, Wu Y, Tang L, Xiong F, Guo C, Li X, Zhou M, Xiang B, Li X, Li G, Xiong W, Zeng Z. Trend analysis of cancer incidence and mortality in China. Sci China Life Sci. 2017;60:1271–5.

    PubMed  Article  PubMed Central  Google Scholar 

  118. 118.

    Torrano V, Valcarcel-Jimenez L, Cortazar AR, Liu X, Urosevic J, Castillo-Martin M, Fernandez-Ruiz S, Morciano G, Caro-Maldonado A, Guiu M, Zuniga-Garcia P, Graupera M, Bellmunt A, Pandya P, Lorente M, Martin-Martin N, Sutherland JD, Sanchez-Mosquera P, Bozal-Basterra L, Zabala-Letona A, Arruabarrena-Aristorena A, Berenguer A, Embade N, Ugalde-Olano A, Lacasa-Viscasillas I, Loizaga-Iriarte A, Unda-Urzaiz M, Schultz N, Aransay AM, Sanz-Moreno V, Barrio R, Velasco G, Pinton P, Cordon-Cardo C, Locasale JW, Gomis RR, Carracedo A. The metabolic co-regulator PGC1alpha suppresses prostate cancer metastasis. Nat Cell Biol. 2016;18:645–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  119. 119.

    Quiros PM, Mottis A, Auwerx J. Mitonuclear communication in homeostasis and stress. Nat Rev Mol Cell Biol. 2016;17:213–26.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  120. 120.

    Canto C, Menzies KJ, Auwerx J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 2015;22:31–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  121. 121.

    Guha M, Avadhani NG. Mitochondrial retrograde signaling at the crossroads of tumor bioenergetics, genetics and epigenetics. Mitochondrion. 2013;13:577–91.

    CAS  PubMed  Article  Google Scholar 

  122. 122.

    Tu C, Zeng Z, Qi P, Li X, Guo C, Xiong F, Xiang B, Zhou M, Liao Q, Yu J, Li Y, Li X, Li G, Xiong W. Identification of genomic alterations in nasopharyngeal carcinoma and nasopharyngeal carcinoma-derived Epstein-Barr virus by whole-genome sequencing. Carcinogenesis. 2018;39:1517–28.

    PubMed  Article  Google Scholar 

  123. 123.

    Schultz MA, Hagan SS, Datta A, Zhang Y, Freeman ML, Sikka SC, Abdel-Mageed AB, Mondal D. Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells. PLoS ONE. 2014;9:e87204.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  124. 124.

    Bugno M, Daniel M, Chepelev NL, Willmore WG. Changing gears in Nrf1 research, from mechanisms of regulation to its role in disease and prevention. Biochem Biophys Acta. 1849;2015:1260–76.

    Google Scholar 

  125. 125.

    Villegas R, Williams SM, Gao YT, Long J, Shi J, Cai H, Li H, Chen CC, Tai ES, Hu F, Cai Q, Zheng W, Shu XO. Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes. Ann Hum Genet. 2014;78:23–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  126. 126.

    Singh S, Simpson RL, Bennett RG. Relaxin activates peroxisome proliferator-activated receptor gamma (PPARgamma) through a pathway involving PPARgamma coactivator 1alpha (PGC1alpha). J Biol Chem. 2015;290:950–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  127. 127.

    Hock MB, Kralli A. Transcriptional control of mitochondrial biogenesis and function. Annu Rev Physiol. 2009;71:177–203.

    CAS  PubMed  Article  Google Scholar 

  128. 128.

    Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends in endocrinology and metabolism: TEM. 2012;23:459–66.

    CAS  PubMed  Article  Google Scholar 

  129. 129.

    Hurtado de Llera A, Martin-Hidalgo D, Gil MC, Garcia-Marin LJ, Bragado MJ. The calcium/CaMKKalpha/beta and the cAMP/PKA pathways are essential upstream regulators of AMPK activity in boar spermatozoa. Biol Reprod. 2014;90:29.

    PubMed  Article  CAS  Google Scholar 

  130. 130.

    Fang EF, Scheibye-Knudsen M, Chua KF, Mattson MP, Croteau DL, Bohr VA. Nuclear DNA damage signalling to mitochondria in ageing. Nat Rev Mol Cell Biol. 2016;17:308–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  131. 131.

    Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19:802–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  132. 132.

    Sekito T, Liu Z, Thornton J, Butow RA. RTG-dependent mitochondria-to-nucleus signaling is regulated by MKS1 and is linked to formation of yeast prion [URE3]. Mol Biol Cell. 2002;13:795–804.

    CAS  PubMed  PubMed Central  Google Scholar 

  133. 133.

    Sekito T, Thornton J, Butow RA. Mitochondria-to-nuclear signaling is regulated by the subcellular localization of the transcription factors Rtg1p and Rtg3p. Mol Biol Cell. 2000;11:2103–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  134. 134.

    Ferreira Junior JR, Spirek M, Liu Z, Butow RA. Interaction between Rtg2p and Mks1p in the regulation of the RTG pathway of Saccharomyces cerevisiae. Gene. 2005;354:2–8.

    CAS  PubMed  Article  Google Scholar 

  135. 135.

    Cardamone MD, Tanasa B, Cederquist CT, Huang J, Mahdaviani K, Li W, Rosenfeld MG, Liesa M, Perissi V. Mitochondrial retrograde signaling in mammals is mediated by the transcriptional cofactor GPS2 via direct mitochondria-to-nucleus translocation. Mol Cell. 2018;69:757–772 e757.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  136. 136.

    Pasini B, Stratakis CA. SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med. 2009;266:19–42.

    CAS  PubMed  Article  Google Scholar 

  137. 137.

    Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L, Micaroni M, Chaneton B, Adam J, Hedley A, Kalna G, Tomlinson IP, Pollard PJ, Watson DG, Deberardinis RJ, Shlomi T, Ruppin E, Gottlieb E. Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature. 2011;477:225–8.

    CAS  PubMed  Article  Google Scholar 

  138. 138.

    Bardella C, Olivero M, Lorenzato A, Geuna M, Adam J, O’Flaherty L, Rustin P, Tomlinson I, Pollard PJ, Di Renzo MF. Cells lacking the fumarase tumor suppressor are protected from apoptosis through a hypoxia-inducible factor-independent, AMPK-dependent mechanism. Mol Cell Biol. 2012;32:3081–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  139. 139.

    Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  140. 140.

    Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA, Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL, Verhaak RG, Yan H, Kaelin WG Jr. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483:484–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  141. 141.

    Vivian CJ, Brinker AE, Graw S, Koestler DC, Legendre C, Gooden GC, Salhia B, Welch DR. Mitochondrial genomic backgrounds affect nuclear DNA methylation and gene expression. Cancer Res. 2017;77:6202–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  142. 142.

    Guha M, Srinivasan S, Ruthel G, Kashina AK, Carstens RP, Mendoza A, Khanna C, Van Winkle T, Avadhani NG. Mitochondrial retrograde signaling induces epithelial-mesenchymal transition and generates breast cancer stem cells. Oncogene. 2014;33:5238–50.

    CAS  PubMed  Article  Google Scholar 

  143. 143.

    He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong W, Li X, Li G, Zeng Z, Tang H. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J Exp Clin Cancer Res. 2017;36:145.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  144. 144.

    Ro S, Ma HY, Park C, Ortogero N, Song R, Hennig GW, Zheng H, Lin YM, Moro L, Hsieh JT, Yan W. The mitochondrial genome encodes abundant small noncoding RNAs. Cell Res. 2013;23:759–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  145. 145.

    Pozzi A, Plazzi F, Milani L, Ghiselli F, Passamonti M. SmithRNAs: could mitochondria “Bend” nuclear regulation? Mol Biol Evol. 2017;34:1960–73.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  146. 146.

    Dong Y, Yoshitomi T, Hu JF, Cui J. Long noncoding RNAs coordinate functions between mitochondria and the nucleus. Epigenetics Chromatin. 2017;10:41.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  147. 147.

    Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, Ren D, Ye X, Li C, Wang Y, Wei F, Guo C, Wu X, Li X, Li Y, Li G, Zeng Z, Xiong W. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018;17:79.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  148. 148.

    Noh JH, Kim KM, Abdelmohsen K, Yoon JH, Panda AC, Munk R, Kim J, Curtis J, Moad CA, Wohler CM, Indig FE, de Paula W, Dudekula DB, De S, Piao Y, Yang X, Martindale JL, de Cabo R, Gorospe M. HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP. Genes Dev. 2016;30:1224–39.

    CAS  PubMed  PubMed Central  Google Scholar 

  149. 149.

    Carden T, Singh B, Mooga V, Bajpai P, Singh KK. Epigenetic modification of miR-663 controls mitochondria-to-nucleus retrograde signaling and tumor progression. J Biol Chem. 2017;292:20694–706.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  150. 150.

    Villegas J, Burzio V, Villota C, Landerer E, Martinez R, Santander M, Martinez R, Pinto R, Vera MI, Boccardo E, Villa LL, Burzio LO. Expression of a novel non-coding mitochondrial RNA in human proliferating cells. Nucleic Acids Res. 2007;35:7336–47.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  151. 151.

    Fan C, Wang J, Tang Y, Wang Y, Xiong F, Zhang S, Li X, Xiang B, Wu X, Guo C, Ma J, Zhou M, Li X, Xiong W, Li Y, Li G, Zeng Z. Long non-coding RNA LOC284454 promotes migration and invasion of nasopharyngeal carcinoma via modulating the Rho/Rac signaling pathway. Carcinogenesis. 2018. https://doi.org/10.1093/carcin/bgy143.

    Article  PubMed  Google Scholar 

Download references

Authors’ contributions

MX, YZ, KJ, ZL collected the related paper, ZZ, WX participated in the design of the review and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

Not applicable.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported in part by grants from the National Natural Science Foundation of China (81572787, 81672683 and 81772928), the Overseas ExpertiseIntroduction Project for Discipline Innovation (111 Project, No. 111–2-12), and the Natural Science Foundation of Hunan Province (2016JC2035, 2017SK2105,2018JJ3704, 2018JJ3815, 2018SK21210 and 2018SK21211).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Author notes

  1. MengFang Xia and YaZhuo Zhang contributed equally to this work

Affiliations

  1. NHC Key Laboratory of Carcinogenesis, Xiangya Hospital, Central South University, Changsha, Hunan, China

    MengFang Xia, YaZhuo Zhang, Zhaoyang Zeng & Wei Xiong

  2. The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan, China

    MengFang Xia, YaZhuo Zhang, Ke Jin, ZiTong Lu, Zhaoyang Zeng & Wei Xiong

  3. Hunan Key Laboratory of Non Resolving Inflammation and Cancer, Disease Genome Research Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China

    MengFang Xia, YaZhuo Zhang, Zhaoyang Zeng & Wei Xiong

Authors
  1. MengFang Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. YaZhuo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ke Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. ZiTong Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhaoyang Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhaoyang Zeng or Wei Xiong.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Xia, M., Zhang, Y., Jin, K. et al. Communication between mitochondria and other organelles: a brand-new perspective on mitochondria in cancer. Cell Biosci 9, 27 (2019). https://doi.org/10.1186/s13578-019-0289-8

Download citation

Keywords

  • Organelle communication
  • Mitochondria
  • Endoplasmic reticulum
  • Peroxisomes
  • Cell nucleus
  • Carcinogenesis

Cell & Bioscience

ISSN: 2045-3701

Contact us